E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy.
In the late 1980s, we have shown that the E1A gene can downregulate HER-2/neu overexpression, thus reversing the tumorigenic and metastatic phenotype. Further, E1A can function as a tumor suppressor gene by inducing apoptosis and inhibiting metastasis. At The University of Texas M. D. Anderson Cancer Center, we have been investigating the adenovirus type 5 E1A gene as a potential therapeutic gene in breast and ovarian cancer since 1995 by using cationic liposome as gene delivery system. In this chapter, we recount our development of E1A as a therapeutic gene.
Ueno
N T
NT
Department of Molecualr and Cellular Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 448, Houston, TX 77030, USA. nueno@mdanderson.org
Yu
D
D
Hung
M C
MC
D017500:Adenovirus E1A Proteins / Q000008:administration & dosage* / Q000235:genetics*; D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D004195:Disease Models, Animal; D005260:Female; D005500:Follow-Up Studies; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051379:Mice; D009856:Oncogene Proteins, Viral / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000628:therapy*; D012680:Sensitivity and Specificity
D017500:Adenovirus E1A Proteins; D009856:Oncogene Proteins, Viral